Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -849.00K | -773.60K | -444.20K | 6.71M | -1.04M |
| Total Depreciation and Amortization | 33.30K | 45.40K | 34.00K | 39.70K | 40.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 140.50K | 285.50K | 96.00K | -7.53M | 156.90K |
| Change in Net Operating Assets | -93.90K | 142.70K | -80.40K | -801.10K | 108.30K |
| Cash from Operations | -769.00K | -299.90K | -394.50K | -1.59M | -730.00K |
| Capital Expenditure | -9.60K | -3.20K | -3.70K | -7.50K | -3.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 52.00K | -- | 6.99M | -- |
| Other Investing Activities | -21.70K | -26.20K | -2.50K | -375.70K | 894.10K |
| Cash from Investing | -31.20K | 22.60K | -6.20K | 6.61M | 890.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -154.70K | -154.30K | -153.90K | -6.15M | -193.10K |
| Issuance of Common Stock | 1.45M | 370.40K | 248.70K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12.90K | -13.40K | -13.80K | -1.42M | -208.00K |
| Cash from Financing | 894.20K | 144.80K | 59.40K | -5.53M | -297.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 0.00 |
| Net Change in Cash | 93.90K | -132.60K | -341.30K | -507.10K | -137.10K |